Equity Details
Price & Market Data
Price: $0.991
Daily Change: -$0.0288 / 2.91%
Daily Range: $0.96 - $1.03
Market Cap: $30,210,412
Daily Volume: 157,027
Performance Metrics
1 Week: 1.68%
1 Month: 7.61%
3 Months: 9.92%
6 Months: -50.26%
1 Year: -70.25%
YTD: -6.73%
About Senti Biosciences Holdings, Inc. (SNTI)
Essential market details for Senti Biosciences Holdings, Inc. (SNTI). Current price: 0.991, daily change: -$0.0288 / 2.91%. Market cap: 30,210,412. Dive into YTD, 1-week, and 6-month performance.
Company Details
Employees: 39
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Senti Biosciences, Inc., a clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. Its lead product candidates utilize off-the-shelf healthy adult donor derived natural killer (NK) cells to create CAR-NK cells outfitted with gene circuit technologies in various oncology indications with unmet need. The company's product candidates also include SENTI-202, a logic gated off-the-shelf CAR-NK cell therapy for the treatment of blood cancers and relapsed/refractory hematological malignancies, including acute myeloid leukemia; and SENTI-301A, an off-the-shelf CAR-NK cell therapy for the treatment of solid tumors and hepatocellular carcinoma. In addition, it develops the tumor-associated antigen and protective antigen paired discovery platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. Further, its pipeline includes preclinical programs, which comprise a solid tumor cell therapy program; and partnered programs related to gene therapies for tissue-directed targets, as well as partnered programs related to cell therapies for regenerative medicines. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.